Pharmacists in Kingman, KS Accepting Medicare
5 Pharmacists found. Showing 1 - 5
 Kinli Simmons, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 211 N Main St, Kingman, KS 67068 Phone: 620-532-5113 |
Dr. Erika Fitzgerald, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 211 N Main St, Kingman, KS 67068 Phone: 620-532-5113 Fax: 620-532-5431 |
 Mr. Gregory Edwin Heikes, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 211 N Main St, Kingman, KS 67068 Phone: 620-532-5113 |
Meredith Voran Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 211 N. Main, Kingman, KS 67068 Phone: 620-532-5113 Fax: 620-532-5431 |
Merlin Mcfarland, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 211 N Main St, Kingman, KS 67068 Phone: 620-532-5113 Fax: 620-532-5431 |
News Archive
Stem-cell finding alters ethical controversy
When University of Wisconsin-Madison researchers succeeded in reprogramming skin cells to behave like embryonic stem cells, they also began to redefine the political and ethical dynamics of the stem-cell debate, a leading bioethicist says. R. Alta Charo, a UW-Madison professor of law and bioethics, says the scientific finding could have far-reaching effects on the social dimensions of the ongoing controversy over embryonic stem cell research.
Exosome-mediated mRNA delivery generates broad immune response to multiple SARS-CoV-2 proteins
Recently, researchers from The Johns Hopkins University School of Medicine, Baltimore, MD, USA, and Capricor Therapeutics, Inc., Beverly Hills, CA, USA, described a new approach to SARS-CoV-2 vaccine development using exosomes to deliver mRNAs that encode the antigens from multiple structural proteins of the virus.
Alnylam receives U.S. patent allowance for LNP platform
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application number 12/813,448, covering the company's proprietary second generation lipid nanoparticle (LNP) platform, including the "MC3" lipid.
New radiopharmaceutical shows therapeutic efficacy in preclinical model of ovarian cancer
Preclinical trials of a new radiopharmaceutical to treat ovarian cancer have produced successful results, dramatically limiting tumor growth and decreasing tumor mass.
› Verified 7 days ago
Pharmacists
Counselors
Marriage Counselors
Psychologists
Clinical Social Workers
Dentists
Occupational Therapists